179 related articles for article (PubMed ID: 10576666)
1. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
de Vries TJ; Fourkour A; Punt CJ; Diepstra H; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(6):1066-70. PubMed ID: 10576666
[TBL] [Abstract][Full Text] [Related]
2. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
3. Detection of tyrosinase mRNA from the blood of melanoma patients.
Stevens GL; Scheer WD; Levine EA
Cancer Epidemiol Biomarkers Prev; 1996 Apr; 5(4):293-6. PubMed ID: 8722221
[TBL] [Abstract][Full Text] [Related]
4. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
de Vries TJ; Fourkour A; Punt CJ; van de Locht LT; Wobbes T; van den Bosch S; de Rooij MJ; Mensink EJ; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 May; 80(5-6):883-91. PubMed ID: 10360670
[TBL] [Abstract][Full Text] [Related]
5. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
de Vries TJ; Fourkour A; Punt CJ; Ruiter DJ; van Muijen GN
Melanoma Res; 2000 Apr; 10(2):119-26. PubMed ID: 10803712
[TBL] [Abstract][Full Text] [Related]
6. Detection of melanoma cells in sentinel lymph nodes by reverse transcriptase-polymerase chain reaction: prognostic significance.
Gradilone A; Ribuffo D; Silvestri I; Cigna E; Gazzaniga P; Nofroni I; Zamolo G; Frati L; Scuderi N; Aglianò AM
Ann Surg Oncol; 2004 Nov; 11(11):983-7. PubMed ID: 15525827
[TBL] [Abstract][Full Text] [Related]
7. The detection of tyrosinase mRNA in the peripheral blood of stage I melanoma patients is not of clinical relevance in predicting metastasis risk and survival.
Aubin F; Chtourou M; Teyssier JR; Laubriet A; Mougin CH; Blanc D; Humbert P
Melanoma Res; 2000 Apr; 10(2):113-8. PubMed ID: 10803711
[TBL] [Abstract][Full Text] [Related]
8. Detection of melanoma cells in the lymphatic drainage after lymph node dissection in melanoma patients by using two-marker reverse transcriptase-polymerase chain reaction assay.
Włodzimierz R; Rutkowski P; Nowecki ZI; Kulik J; Nasierowska-Guttmejer A; Siedlecki JA
Ann Surg Oncol; 2004 Nov; 11(11):988-97. PubMed ID: 15525828
[TBL] [Abstract][Full Text] [Related]
9. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin.
Hau P; Apfel R; Wiese P; Tschertner I; Blesch A; Bogdahn U
Anticancer Res; 2002; 22(2A):577-83. PubMed ID: 12014625
[TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of tyrosinase and tyrosinase-related protein-2 mRNA from melanoma cells in blood by real-time polymerase chain reaction.
Johansson M; Arstrand K; Håkansson A; Lindholm C; Kågedal B
Melanoma Res; 2000 Jun; 10(3):213-22. PubMed ID: 10890374
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients.
Garbe C; Leiter U; Ellwanger U; Blaheta HJ; Meier F; Rassner G; Schittek B
Cancer; 2003 Apr; 97(7):1737-45. PubMed ID: 12655531
[TBL] [Abstract][Full Text] [Related]
12. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
13. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
14. Expression of melanoma inhibitory activity in melanoma and nonmelanoma tissue specimens.
Perez RP; Zhang P; Bosserhoff AK; Buettner R; Abu-Hadid M
Hum Pathol; 2000 Nov; 31(11):1381-8. PubMed ID: 11112213
[TBL] [Abstract][Full Text] [Related]
15. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method.
Arenberger P; Arenbergerova M; Gkalpakiotis S; Lippert J; Stribrna J; Kremen J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):56-64. PubMed ID: 18181974
[TBL] [Abstract][Full Text] [Related]
16. Detection of tyrosinase mRNA by an optimised nested RT-PCR in the peripheral blood of patients with advanced malignant melanoma.
Glumac N; Hocevar M; Snoj M; Novakovic S
J Exp Clin Cancer Res; 2001 Dec; 20(4):529-36. PubMed ID: 11876547
[TBL] [Abstract][Full Text] [Related]
17. Optimization of the tyrosinase mRNA probe to detect circulating melanocytes with reverse transcription and polymerase chain reaction.
Carrillo E; Marchal JA; Prados J; Melguizo C; Vélez C; Arena N; Alvarez L; Serrano S; Aránega A
Cell Mol Biol (Noisy-le-grand); 1998 Dec; 44(8):1247-52. PubMed ID: 9874512
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and diagnostic value of protein S-100 and tyrosinase in patients with malignant melanoma.
Andrés R; Mayordomo JI; Visus C; Isla D; Godino J; Escudero P; Saenz A; Ortega E; Lastra R; Lambea J; Aguirre E; Elosegui L; Marcos I; Ruiz-Echarri M; Millastre E; Sáez-Gutierrez B; Asin L; Vidal MJ; Ferrer A; Giner A; Larrad L; Carapeto FJ; Tres A
Am J Clin Oncol; 2008 Aug; 31(4):335-9. PubMed ID: 18845991
[TBL] [Abstract][Full Text] [Related]
19. Detection of circulating malignant cells by RT-PCR in long-term clinically disease-free I stage melanoma patients.
Baldi A; Dragonetti E; Battista T; Groeger AM; Esposito V; Baldi G; Santini D
Anticancer Res; 2000; 20(5C):3923-8. PubMed ID: 11268478
[TBL] [Abstract][Full Text] [Related]
20. Comparison between three molecular methods for detection of blood melanoma tyrosinase mRNA. Correlation with melanoma stages and S100B, LDH, NSE biochemical markers.
Santonocito C; Concolino P; Lavieri MM; Ameglio F; Gentileschi S; Capizzi R; Rocchetti S; Amerio P; Castagnola M; Zuppi C; Capoluongo E
Clin Chim Acta; 2005 Dec; 362(1-2):85-93. PubMed ID: 16054123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
